<p>根据 Annex Advisory Services LLC 在最近向证券交易委员会提交的 Form 13F 文件，该公司在第四季度将其在史赛克公司（NYSE:SYK - 免费报告）的持股减少了 87.1%。该机构投资者在此期间出售了 15,163 股后，持有 2,245 股该医疗技术公司的股票。根据其最近向证券交易委员会的文件，Annex Advisory Services LLC 在史赛克的持股价值为 789,000 美元。</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他一些对冲基金也增加或减少了在 SYK 的持股。Clayton Financial Group LLC 在第三季度购买了价值 26,000 美元的史赛克新头寸。United Financial Planning Group LLC 在第三季度购买了价值 27,000 美元的史赛克新头寸。Strive Asset Management LLC 在第三季度购买了价值 30,000 美元的史赛克新头寸。ANTIPODES PARTNERS Ltd 在第三季度购买了价值 34,000 美元的史赛克新头寸。最后，Copia Wealth Management 在第三季度将其在史赛克的持股增加了 181.6%。Copia Wealth Management 现在拥有 107 股该医疗技术公司的股票，价值 40,000 美元，此前在上个季度又购买了 69 股。机构投资者持有该公司 77.09% 的股票。</p>
<h2>内部人士下注</h2>
<p>在其他史赛克新闻中，董事 Ronda E. Stryker 于 2 月 4 日星期三出售了 250,000 股史赛克股票。该股票以平均价格 362.92 美元出售，总价值为 90,730,000.00 美元。出售完成后，该董事在公司中持有 2,457,331 股，价值 891,814,566.52 美元。此次交易使其持股减少了 9.23%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。公司内部人士持有 4.60% 的股票。</p>
<h2>史赛克价格表现</h2>
<ul>
<li>为什么内部人士正在抛售 Robinhood、史赛克和 Mercury Systems 的股票？</li>
</ul>
<p>史赛克股票在星期四开盘价为 341.74 美元。史赛克公司过去 12 个月的最低价为 319.32 美元，最高价为 404.87 美元。该公司的速动比率为 1.21，流动比率为 1.89，债务与股本比率为 0.66。该公司的 50 日简单移动平均线为 353.78 美元，200 日简单移动平均线为 359.95 美元。该股票的市值为 1308.8 亿美元，市盈率为 40.68，市盈增长比率为 2.02，贝塔值为 0.92。</p>
<p>史赛克（NYSE:SYK - 获取免费报告）最近在 1 月 29 日星期四发布了季度财报。该医疗技术公司报告本季度每股收益为 4.47 美元，超出市场共识预期的 4.40 美元，超出幅度为 0.07 美元。史赛克的净利润率为 12.92%，股本回报率为 24.41%。该公司本季度的收入为 71.7 亿美元，而分析师预期为 71.2 亿美元。去年同期，该公司每股收益为 4.01 美元。该公司的收入同比增长了 11.4%。分析师预测史赛克公司本年度将发布 13.47 美元的每股收益。</p>
<h2>史赛克宣布分红</h2>
<ul>
<li>当心死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
<p>该公司还最近披露了季度分红，将于 4 月 30 日星期四支付。3 月 31 日星期二的股东将获得 0.88 美元的分红。除息日为 3 月 31 日星期二。这代表着每年 3.52 美元的分红，收益率为 1.0%。史赛克的派息比率为 41.90%。</p>
<h2>分析师评级变动</h2>
<p>一些研究分析师最近对 SYK 股票进行了评估。Citizens Jmp 将史赛克的股票评级从 “市场表现” 上调至 “跑赢大盘”，并在 12 月 19 日的研究报告中设定了 440.00 美元的目标价。Sanford C. Bernstein 在 1 月 9 日的研究报告中将史赛克的目标价从 450.00 美元上调至 465.00 美元，并给予该公司 “跑赢大盘” 的评级。William Blair 在 3 月 5 日的研究报告中重申了对史赛克的 “跑赢大盘” 评级。Weiss Ratings 在 12 月 22 日的研究报告中重申了对史赛克的 “持有（c+）” 评级。最后，Barclays 在 2 月 2 日的研究报告中重申了 “增持” 评级，并对史赛克的股票设定了 469.00 美元的目标价。十五位股票研究分析师对该股票给予了买入评级，六位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 421.11 美元。</p>
<p><strong>阅读我们关于史赛克的最新研究报告</strong></p>
<h2>影响史赛克的关键头条</h2>
<p>以下是本周影响史赛克的关键新闻故事：</p>
<ul>
<li>积极情绪：Stryker 同意收购 Amplitude Vascular Systems，以增加下一代 IVL 技术，扩展其外周血管产品，并可能加速动脉疾病的可寻址市场增长——这是一个战略性的收购，投资者普遍认为这将促进增长。Stryker 收购 AVS (Zacks)</li>
<li>积极情绪：BTIG 重申了买入评级，并设定了 397 美元的目标价，表明分析师对 Stryker 增长的持续信心，并支持该股的上涨预期。BTIG 重申买入</li>
<li>积极情绪：Leerink Partners 对 Stryker 开始覆盖，给予超越市场表现的推荐，增加了另一个支持性的机构观点，可能有助于长期支撑该股。Leerink 开始覆盖 (MSN)</li>
<li>中性情绪：AmericanBankingNews 发布了单独的启动通知；启动增加了机构覆盖和流动性，但其即时方向性影响取决于报告的立场和投资者反应。Leerink 开始覆盖 (AmericanBankingNews)</li>
<li>消极情绪：Truist 将其目标价从 395 美元下调至 380 美元，并调整为 “持有” 评级，降低了隐含的上涨空间，并导致一些投资者在目标价下调时进行短期抛售。Truist 下调目标价 (Benzinga)</li>
</ul>
<h2>Stryker 公司简介</h2>
<p>(免费报告)</p>
<p>Stryker Corporation 是一家全球医疗技术公司，设计、制造和销售广泛的产品和服务，供医院、外科医生办公室和其他医疗机构使用。其主要业务活动涵盖骨科（包括关节置换植入物、创伤和肢体产品）、外科设备和手术室技术（如可视化、导航和电动仪器）、神经技术和脊柱解决方案，以及病人搬运和紧急医疗设备。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Stryker 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Stryker 吗？</h2>
<p>在你考虑 Stryker 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Stryker 并不在名单上。</p>
<p>虽然 Stryker 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

史赛克

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>Annex Advisory Services LLC 大幅减少了在 Stryker Corporation (NYSE:SYK) 的持股，减少幅度达到 87.1%，在第四季度出售了 15,163 股。出售后，他们目前持有 2,245 股，价值 789,000 美元。其他机构投资者也调整了在 Stryker 的持股。此外，董事 Ronda E. Stryker 出售了 250,000 股，交易金额约为 9073 万美元。Stryker 的股票开盘价为 341.74 美元，市值为 1308.8 亿美元，最近的季度财报显示净利润率为 12.92%。公司宣布季度股息为 0.88 美元，将于 4 月 30 日支付</p>

<p>Annex Advisory Services LLC lowered its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 87.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,245 shares of the medical technology company's stock after selling 15,163 shares during the period. Annex Advisory Services LLC's holdings in Stryker were worth $789,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>根据 Annex Advisory Services LLC 在最近向证券交易委员会提交的 Form 13F 文件，该公司在第四季度将其在史赛克公司（NYSE:SYK - 免费报告）的持股减少了 87.1%。该机构投资者在此期间出售了 15,163 股后，持有 2,245 股该医疗技术公司的股票。根据其最近向证券交易委员会的文件，Annex Advisory Services LLC 在史赛克的持股价值为 789,000 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>A number of other hedge funds have also added to or reduced their stakes in SYK. Clayton Financial Group LLC bought a new position in Stryker in the third quarter valued at $26,000. United Financial Planning Group LLC bought a new position in Stryker in the third quarter valued at $27,000. Strive Asset Management LLC bought a new position in Stryker in the third quarter valued at $30,000. ANTIPODES PARTNERS Ltd bought a new position in Stryker in the third quarter valued at $34,000. Finally, Copia Wealth Management grew its position in Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 77.09% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金也增加或减少了在 SYK 的持股。Clayton Financial Group LLC 在第三季度购买了价值 26,000 美元的史赛克新头寸。United Financial Planning Group LLC 在第三季度购买了价值 27,000 美元的史赛克新头寸。Strive Asset Management LLC 在第三季度购买了价值 30,000 美元的史赛克新头寸。ANTIPODES PARTNERS Ltd 在第三季度购买了价值 34,000 美元的史赛克新头寸。最后，Copia Wealth Management 在第三季度将其在史赛克的持股增加了 181.6%。Copia Wealth Management 现在拥有 107 股该医疗技术公司的股票，价值 40,000 美元，此前在上个季度又购买了 69 股。机构投资者持有该公司 77.09% 的股票。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. 4.60% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他史赛克新闻中，董事 Ronda E. Stryker 于 2 月 4 日星期三出售了 250,000 股史赛克股票。该股票以平均价格 362.92 美元出售，总价值为 90,730,000.00 美元。出售完成后，该董事在公司中持有 2,457,331 股，价值 891,814,566.52 美元。此次交易使其持股减少了 9.23%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。公司内部人士持有 4.60% 的股票。</p>
</div><h2>Stryker Price Performance</h2>
<div class="lb-trans"><h2>史赛克价格表现</h2>
</div><ul>
<li>Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么内部人士正在抛售 Robinhood、史赛克和 Mercury Systems 的股票？</li>
</ul>
</div><p>Shares of Stryker stock opened at $341.74 on Thursday. Stryker Corporation has a twelve month low of $319.32 and a twelve month high of $404.87. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The company has a 50-day simple moving average of $353.78 and a two-hundred day simple moving average of $359.95. The stock has a market capitalization of $130.88 billion, a price-to-earnings ratio of 40.68, a price-to-earnings-growth ratio of 2.02 and a beta of 0.92.</p>
<div class="lb-trans"><p>史赛克股票在星期四开盘价为 341.74 美元。史赛克公司过去 12 个月的最低价为 319.32 美元，最高价为 404.87 美元。该公司的速动比率为 1.21，流动比率为 1.89，债务与股本比率为 0.66。该公司的 50 日简单移动平均线为 353.78 美元，200 日简单移动平均线为 359.95 美元。该股票的市值为 1308.8 亿美元，市盈率为 40.68，市盈增长比率为 2.02，贝塔值为 0.92。</p>
</div><p>Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion during the quarter, compared to analysts' expectations of $7.12 billion. During the same quarter in the previous year, the company earned $4.01 EPS. The business's revenue was up 11.4% on a year-over-year basis. Analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.</p>
<div class="lb-trans"><p>史赛克（NYSE:SYK - 获取免费报告）最近在 1 月 29 日星期四发布了季度财报。该医疗技术公司报告本季度每股收益为 4.47 美元，超出市场共识预期的 4.40 美元，超出幅度为 0.07 美元。史赛克的净利润率为 12.92%，股本回报率为 24.41%。该公司本季度的收入为 71.7 亿美元，而分析师预期为 71.2 亿美元。去年同期，该公司每股收益为 4.01 美元。该公司的收入同比增长了 11.4%。分析师预测史赛克公司本年度将发布 13.47 美元的每股收益。</p>
</div><h2>Stryker Announces Dividend</h2>
<div class="lb-trans"><h2>史赛克宣布分红</h2>
</div><ul>
<li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>当心死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker's payout ratio is 41.90%.</p>
<div class="lb-trans"><p>该公司还最近披露了季度分红，将于 4 月 30 日星期四支付。3 月 31 日星期二的股东将获得 0.88 美元的分红。除息日为 3 月 31 日星期二。这代表着每年 3.52 美元的分红，收益率为 1.0%。史赛克的派息比率为 41.90%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research analysts recently weighed in on SYK shares. Citizens Jmp raised shares of Stryker from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $440.00 target price for the company in a research report on Friday, December 19th. Sanford C. Bernstein raised their target price on shares of Stryker from $450.00 to $465.00 and gave the company an &#34;outperform&#34; rating in a research report on Friday, January 9th. William Blair reissued an &#34;outperform&#34; rating on shares of Stryker in a research report on Thursday, March 5th. Weiss Ratings reissued a &#34;hold (c+)&#34; rating on shares of Stryker in a research report on Monday, December 22nd. Finally, Barclays reissued an &#34;overweight&#34; rating and issued a $469.00 price objective on shares of Stryker in a research report on Monday, February 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $421.11.</p>
<div class="lb-trans"><p>一些研究分析师最近对 SYK 股票进行了评估。Citizens Jmp 将史赛克的股票评级从 “市场表现” 上调至 “跑赢大盘”，并在 12 月 19 日的研究报告中设定了 440.00 美元的目标价。Sanford C. Bernstein 在 1 月 9 日的研究报告中将史赛克的目标价从 450.00 美元上调至 465.00 美元，并给予该公司 “跑赢大盘” 的评级。William Blair 在 3 月 5 日的研究报告中重申了对史赛克的 “跑赢大盘” 评级。Weiss Ratings 在 12 月 22 日的研究报告中重申了对史赛克的 “持有（c+）” 评级。最后，Barclays 在 2 月 2 日的研究报告中重申了 “增持” 评级，并对史赛克的股票设定了 469.00 美元的目标价。十五位股票研究分析师对该股票给予了买入评级，六位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 421.11 美元。</p>
</div><p><strong>Read Our Latest Research Report on Stryker</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于史赛克的最新研究报告</strong></p>
</div><h2>Key Headlines Impacting Stryker</h2>
<div class="lb-trans"><h2>影响史赛克的关键头条</h2>
</div><p>Here are the key news stories impacting Stryker this week:</p>
<div class="lb-trans"><p>以下是本周影响史赛克的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Stryker agreed to acquire Amplitude Vascular Systems to add next‑generation IVL technology, expanding its peripheral vascular offerings and potentially accelerating addressable market growth in arterial disease — a strategic tuck‑in that investors generally view as growth‑accretive. Stryker to Acquire AVS (Zacks)</li>
<li>Positive Sentiment: BTIG reaffirmed a Buy rating and set a $397 price target, signaling continued analyst confidence in Stryker's growth and supporting upside expectations for the stock. BTIG Buy Reaffirmed</li>
<li>Positive Sentiment: Leerink Partners initiated coverage on Stryker with an outperform/recommendation, adding another supportive institutional view that may help underpin the stock over time. Leerink Initiates Coverage (MSN)</li>
<li>Neutral Sentiment: A separate initiation notice was posted by AmericanBankingNews; initiation increases institutional coverage and liquidity but its immediate directional impact depends on the report's stance and investor reaction. Leerink Initiates Coverage (AmericanBankingNews)</li>
<li>Negative Sentiment: Truist lowered its price target from $395 to $380 and moved to a &#34;hold&#34; rating, reducing the implied upside and contributing to near‑term selling pressure as some investors mark positions to the lower PT. Truist Lowers Price Target (Benzinga)</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Stryker 同意收购 Amplitude Vascular Systems，以增加下一代 IVL 技术，扩展其外周血管产品，并可能加速动脉疾病的可寻址市场增长——这是一个战略性的收购，投资者普遍认为这将促进增长。Stryker 收购 AVS (Zacks)</li>
<li>积极情绪：BTIG 重申了买入评级，并设定了 397 美元的目标价，表明分析师对 Stryker 增长的持续信心，并支持该股的上涨预期。BTIG 重申买入</li>
<li>积极情绪：Leerink Partners 对 Stryker 开始覆盖，给予超越市场表现的推荐，增加了另一个支持性的机构观点，可能有助于长期支撑该股。Leerink 开始覆盖 (MSN)</li>
<li>中性情绪：AmericanBankingNews 发布了单独的启动通知；启动增加了机构覆盖和流动性，但其即时方向性影响取决于报告的立场和投资者反应。Leerink 开始覆盖 (AmericanBankingNews)</li>
<li>消极情绪：Truist 将其目标价从 395 美元下调至 380 美元，并调整为 “持有” 评级，降低了隐含的上涨空间，并导致一些投资者在目标价下调时进行短期抛售。Truist 下调目标价 (Benzinga)</li>
</ul>
</div><h2>Stryker Company Profile</h2>
<div class="lb-trans"><h2>Stryker 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.</p>
<div class="lb-trans"><p>Stryker Corporation 是一家全球医疗技术公司，设计、制造和销售广泛的产品和服务，供医院、外科医生办公室和其他医疗机构使用。其主要业务活动涵盖骨科（包括关节置换植入物、创伤和肢体产品）、外科设备和手术室技术（如可视化、导航和电动仪器）、神经技术和脊柱解决方案，以及病人搬运和紧急医疗设备。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Stryker</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Stryker 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=SYK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Stryker Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Stryker 吗？</h2>
</div><p>Before you consider Stryker, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Stryker 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Stryker 并不在名单上。</p>
</div><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Stryker 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Annex Advisory Services LLC 出售了 15,163 股史赛克公司股票，代码为$SYK